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Abstract: OBJECTIVES To compare virologic and immunologic outcomes of integrase inhibitor (INSTI)-
containing, contemporary boosted protease inhibitor (PI/b)-containing and non-nucleotide reverse tran-
scriptase inhibitor (NNRTI)-containing regimens in a real-life setting. METHODS Using logistic regres-
sion, virologic and immunologic outcomes of INSTI use were compared to outcomes of PI/b or NNRTI
treatment 12 months after treatment start or switch, for participants in the RESPOND cohort consortium.
A composite treatment outcome (cTO) was used, defining success as viral load (VL) <200 copies/mL
and failure as at least one of: VL ฀200 copies/mL, unknown VL in the time window, any changes of
antiretroviral therapy (ART) regimen, AIDS, or death. In addition, on-treatment analysis including only
individuals with known VL and no regimen changes was performed. Favorable immunologic response was
defined as a 25% increase in CD4 count or as reaching ฀750 CD4 cells/฀L. RESULTS Between January 2012
and January 2019, 13,703 (33.0% ART-naïve) individuals were included, of whom 7,147 started/switched
to a regimen with an INSTI, 3,102 to a PI/b and 3,454 to an NNRTI-containing regimen. The main
reason for cTO failure in all treatment groups were changes in ART regimen. Compared to INSTIs, the
adjusted odds ratio (aOR) of cTO success was significantly lower for PI/b (0.74 [95% confidence interval,
CI 0.67-0.82], p <0.001), but similar for NNRTIs (1.07 [CI 0.97-1.17], p = 0.11). On-treatment analysis
and sensitivity analyses using a VL cut-off of 50 copies/mL were consistent. Compared to INSTIs, the
aORs of a 25% increase in CD4 count were lower for NNRTIs (0.80 [CI 0.71-0.91], p<0.001) and PI/b
(0.87 [CI 0.76-0.99], p = 0.04). CONCLUSION In this large analysis of a real-world population, cTO
and on-treatment success were similar between INSTIs and NNRTIs, but lower for PI/b, though residual
confounding cannot be fully excluded. Obtaining favorable immunologic outcomes were more likely for
INSTIs than the other drug classes.
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Methods
Using logistic regression, virologic and immunologic outcomes of INSTI use were compared
to outcomes of PI/b or NNRTI treatment 12 months after treatment start or switch, for partici-
pants in the RESPOND cohort consortium. A composite treatment outcome (cTO) was
used, defining success as viral load (VL) <200 copies/mL and failure as at least one of: VL
�200 copies/mL, unknown VL in the time window, any changes of antiretroviral therapy
(ART) regimen, AIDS, or death. In addition, on-treatment analysis including only individuals
with known VL and no regimen changes was performed. Favorable immunologic response
was defined as a 25% increase in CD4 count or as reaching�750 CD4 cells/μL.
Results
Between January 2012 and January 2019, 13,703 (33.0% ART-naïve) individuals were
included, of whom 7,147 started/switched to a regimen with an INSTI, 3,102 to a PI/b and
3,454 to an NNRTI-containing regimen. The main reason for cTO failure in all treatment
groups were changes in ART regimen. Compared to INSTIs, the adjusted odds ratio (aOR)
of cTO success was significantly lower for PI/b (0.74 [95% confidence interval, CI 0.67–
0.82], p <0.001), but similar for NNRTIs (1.07 [CI 0.97–1.17], p = 0.11). On-treatment analy-
sis and sensitivity analyses using a VL cut-off of 50 copies/mL were consistent. Compared
to INSTIs, the aORs of a 25% increase in CD4 count were lower for NNRTIs (0.80 [CI 0.71–
0.91], p<0.001) and PI/b (0.87 [CI 0.76–0.99], p = 0.04).
Conclusion
In this large analysis of a real-world population, cTO and on-treatment success were similar
between INSTIs and NNRTIs, but lower for PI/b, though residual confounding cannot be
fully excluded. Obtaining favorable immunologic outcomes were more likely for INSTIs than
the other drug classes.
Introduction
Integrase inhibitors (INSTIs) have excelled in randomized clinical trials (RCTs) by showing
potent and swift suppression of human immunodeficiency virus (HIV), good short-term drug
safety and tolerability, and, for second generation INSTIs, high genetic barriers to resistance
[1–7]. In turn, this has led to INSTI-based regimens being recommended as first-line antire-
troviral therapy (ART) by European, North American andWHO guidelines, above or along-
side contemporary ritonavir- or cobicistat-boosted protease inhibitor (PI/b)-containing and
non-nucleotide reverse transcriptase inhibitor (NNRTI)-containing regimens [8–12]. How-
ever, RCTs typically enroll only a modestly sized and selected study population, where females,
individuals with high HIV viral loads (VLs), low CD4 counts, comorbidities or coinfections
are commonly underrepresented. Results from RCTs should therefore be complemented by
investigations from large, heterogeneous, real-life, observational studies, ensuring that findings
from RCTs are generalizable to the majority of people living with HIV (PLWH).
In this study we analysed virologic and immunologic outcomes of INSTI-containing regi-
mens compared to contemporary PI/b- and NNRTI-containing regimens within the large het-
erogenous RESPOND cohort consortium.
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The RESPOND cohort consortium (https://chip.dk/Studies/RESPOND) was initiated in 2017
as an international collaboration between 17 pre-existing, prospective European and Austra-
lian based cohorts of HIV-1 positive participants (see S1 Appendix for RESPOND inclusion/
exclusion criteria). At present, the RESPOND consortium follows>29,000 PLWH.
The Outcomes Study under the consortium was formed to investigate use and outcomes of
treatment with contemporary ART [13]. Information systematically collected on all partici-
pants includes demographics (e.g. age, sex and ethnicity), HIV related variables (e.g. VL, CD4
counts, route of HIV acquisition and AIDS events), detailed information on ART use and rea-
sons for discontinuation, laboratory measures (e.g. creatinine, liver transferases and glucose),
comorbidities (e.g. diabetes, hypertension and viral hepatitis coinfections) [14]. In addition,
incident clinical events including cancer, cardiovascular, renal and liver disease are reported
on designated forms and centrally validated. All collected data is transferred electronically to
RESPOND, and undergoes extensive quality assessments [14].
Ethics
All studies carried out within the RESPOND consortium are conducted according to the Dec-
laration of Helsinki and the requirements of Good Clinical Practice (GCP) as defined in the
European Union’s (EU) GCP Directive. All data supplied to RESPOND follows local or
national guidelines as appropriate, and enrolled participants are pseudonymized by assign-
ment of a unique identifier, by the participating cohort before data transfer. As data controller,
the Coordinating Centre (CC) located within the Danish Capital Region of Copenhagen,
Denmark, stores, shares and protects data in accordance with current legislation and under
approval by The Danish Data Protection Agency (j.nr.: RH-2018-15, 26/1/2018), currently
under the EU’s General Data Protection Regulation (EU) 2016/679.
RESPOND is registered at Clinicaltrials.gov (Identifier: NCT04090151).
Inclusion criteria
For this specific analysis, we included ART-naïve and -experienced individuals, aged over 18
years who started or switched to an INSTI, PI/b or NNRTI-containing regimen with at least
three antiretroviral drugs (ARVs). The eligible regimen was started between January 2012 and
January 2019, and all included had a CD4 count and VL measured in the 12 months before or
3 months after treatment start/switch (baseline). Treatment-experienced individuals were
naïve to the specific third agent they started when eligible for inclusion (e.g. an individual
switching to darunavir had not previously been treated with darunavir).
Definition of outcomes
All outcomes were assessed 12 months after baseline. The VL and CD4 count closest to this
time were used, allowing a maximum time window of 3 months to either side (12±3 months).
To estimate the durability of regimens, a composite treatment outcome (cTO) was used,
defining treatment success as VL<200 copies(cp)/mL and failure as occurrence of at least
one of either: VL�200 copies (cp)/mL, unknown VL in the time window, any ART regimen
change, AIDS event, or death. Switching from a multi-tablet combination regimen to a single-
tablet combination regimen including the same agents, or vice versa, was not considered as a
regimen change. Conversely, switch to a two-drug regimen and/or any changes in individual
regimen components were viewed as regimen changes (e.g. if tenofovir disoproxil fumarate
PLOS ONE Outcomes of integrase inhibitors treatment
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[TDF] was changed to tenofovir alafenamide [TAF], it was regarded as a treatment change, as
it could be related to drug toxicity).
Sensitivity analyses tested the robustness of the cTO by excluding either individuals with
unknown VL values within the time widow or those with any regimen change. Furthermore,
an analysis which did not define changes in the NRTI backbone as a regimen change was
performed.
Additionally, the efficacy of the regimens to control HIV (VL<200 cp/mL) was estimated
using on-treatment analysis, including only individuals with a known VL at 12±3 months and
no regimen changes within the period.
The use of a VL<200 cp/mL threshold for the cTO and on-treatment analysis followed a
consensus agreement within the RESPOND virologic outcomes working group, reflecting dif-
ferences in the sensitivity of VL assays available in different cohorts. Sensitivity analyses using
a VL<50 cp/mL threshold were also performed.
A favorable immunologic response was defined as a 25% increase in CD4 count from base-
line. As individuals with high CD4 counts at baseline would presumably have lower odds of
reaching such an increase, we also defined a favorable immunologic response as reaching CD4
count�750 cells/μL (excluding those with CD4 count�750 cells/μL at baseline), following the
rationale described in earlier work by Mocroft et al. [15].
To ascertain if there were any variations in outcomes depending on treatment status at
baseline, outcomes were determined for three pre-specified sub-groups: ART-naïve individu-
als, ART-experienced individuals switching to a new ART-regimen with ongoing viremia
(�200 cp/mL), and ART-experienced individuals switching to a new ART-regimen with viro-
logic control (<200 cp/mL). Given the heterogeneity of the populations, tests for interactions
between ART-experience and treatment status at baseline for each outcome were planned a
priori.
Statistics
Descriptive statistics were summarized as frequencies and proportions with χ2 P-values for
categorical variables. For continuous variables, data were presented as medians and interquar-
tile ranges (IQR), with P-values from the Wilcoxon-Mann-Whitney test.
Virologic and immunologic outcomes for individuals starting/switching to an INSTI
(dolutegravir, raltegravir or cobicistat-boosted elvitegravir)-containing regimen were com-
pared to participants starting/switching to a PI/b (ritonavir- or cobicistat-boosted darunavir
or atazanavir)-containing or NNRTI (rilpivirine or efavirenz)-containing regimen, using sepa-
rate logistic regression models.
Factors considered for multivariable analyses included demographics (age, sex, and ethnic-
ity) and region of origin, categorized as West Central Europe (Austria, Belgium, France, Ger-
many, Luxembourg, Switzerland), South Europe and Argentina (Argentina, Greece, Israel,
Italy, Portugal, Spain), North Europe and Australia (Australia, Denmark, Norway, Sweden,
Finland, Iceland, Ireland, Netherlands, United Kingdom; Australia was included here based
on the small number of individuals, and similarities with the United Kingdom), East Central
Europe (Bosnia-Herzegovina, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia,
Slovenia, Slovakia) and East Europe (Belarus, Estonia, Georgia, Latvia, Lithuania, Russia,
Ukraine). Other variables included HIV-related factors (VL, CD4 count, route of HIV acquisi-
tion, ART, and prior AIDS), hepatitis B and C coinfection, cardiovascular risk factors (smok-
ing status, hypertension and diabetes) and other non-AIDS events (chronic kidney disease,
end stage liver-and renal disease, cardiovascular disease, fractures and malignancies). All
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factors included in the models were decided a priori. Full lists of variables included in the spe-
cific multivariate models are shown in the figure legends.
As some cohorts did not have complete data on comorbidities, it was not possible to adjust
for both cohort and comorbidities in the same analyses, due to the risk of collinearity. There-
fore, our main analyses focused on adjusting for comorbidities as listed above, while acknowl-
edging that there was some missing data. Sensitivity analyses adjusting for cohort rather than
comorbidities were also performed.
Finally, sensitivity analyses restricted to ART-naïve individuals starting treatment after 16th
January 2014 (the date dolutegravir was licensed in Europe) were performed.
All analyses were performed using SAS (Statistical Analysis Software, Cary, NC, US) version
9.4., all tests of significance were 2-sided with p<0.05 used for statistical significance and all
confidence intervals (CI) were 95%.
Results
Baseline demographics and clinical characteristics
In total, 13,703 participants were included (Table 1). Of these, 4,967 (52.2%) were treated with
an INSTI (dolutegravir 3,839, raltegravir 1,738 and elvitegravir 1,570), 3,102 (22.6%) with a PI/
b (darunavir/b 2,381, atazanavir/b 721), and 3,454 (25.9%) with an NNRTI-containing regi-
men (rilpivirine 2,508, efavirenz 946). The most common nucleos(t)ide reverse transcriptase
inhibitor (NRTI) backbone used in all three treatment groups was TDF/emtricitabine (FTC),
followed by abacavir (ABC)/lamivudine (3TC) in the INSTI and PI/b groups and TAF/FTC in
the NNRTI group. Median time since initiation of first ARV was longest for individuals in the
INSTI group (13 years [IQR 7–18]) followed by individuals in the PI/b and NNRTI groups (10
[5–16] and 8 [4–14], respectively). Likewise, the median number of ARVs previously exposed
to, was slightly higher in the INSTI group (6 [4–9]) than in the PI/b and NNRTI groups (5 [3–
8] and 5 [3–7], respectively). At baseline, ART-naïve individuals constituted 26.8%, 40.2% and
41.7% of the INSTI, PI/b and NNRTI groups, respectively. There was a greater proportion of
ART-experienced individuals with VL<200 cp/mL in the INSTI group compared to the PI/b
and NNRTI groups (65.7% vs. 43.6% and 55.6%, respectively). Baseline characteristics strati-
fied by treatment status at baseline are provided in S1 Table.
Overall, 75.3% of those included were of male sex, with men who have sex with men
(MSM) being the most common route of HIV acquisition (46.1%; Table 1). The most common
region of origin was West Central Europe (53.7%), followed by South Europe and Argentina
(27.9%) and North Europe and Australia (10.9%). Median age was slightly higher in the INSTI
group than in the PI/b or NNRTI groups (48 [IQR 39–54] years vs. 43 [35–51] and 43 [36–51]
years, respectively). Median CD4 count was highest for individuals on INSTIs in comparison
with individuals on PI/b or NNRTIs (551 [IQR 359–761] cells/μL vs. 411 [230–624] or 510
[356–710] cells/μL, respectively). Furthermore, a greater proportion of current smokers, indi-
viduals with BMI>25 kg/m2, and comorbidities such as hypertension, diabetes, chronic kid-
ney disease and prior cardiovascular disease, was found in the INSTI group compared the
other two treatment groups. All p-values for all comparison of baseline characteristics between
treatment groups were< 0.001.
Virologic outcomes
The crude proportion of cTO success was lowest in the PI/b group, while being fairly similar
between the INSTI and NNRTI groups (52.1% [95% CI 50.3–53.9] vs. 61.5% [60.4–62.7] and
63.7% [62.1–65.3], p<0.001 respectively; Fig 1). Similar results were seen after adjustments.
The adjusted odds ratio (aOR) of cTO success was significantly lower for PI/b compared to
PLOS ONE Outcomes of integrase inhibitors treatment
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Table 1. Baseline demographics and clinical characteristics of study participants, stratified by treatment group.
All INSTI PI/b NNRTI
n % n % n % n %
13703 100.0 7147 52.2 3102 22.6 3454 25.2
Sex Female 3390 24.7 1693 23.7 936 30.2 761 22.0
Male 10313 75.3 5454 76.3 2166 69.8 2693 78.0
Ethnicity White 9625 70.2 5049 70.6 2061 66.4 2515 72.8
Other 2162 15.8 994 13.9 638 20.6 530 15.3
Unknown 1916 14.0 1104 15.4 403 13.0 409 11.8
Region South Europe and Argentina 3825 27.9 1752 24.5 943 30.4 1130 32.7
West Central Europe 7364 53.7 4121 57.7 1608 51.8 1635 47.3
North Europe and Australia 1489 10.9 885 12.4 296 9.5 308 8.9
Central East Europe 623 4.5 325 4.5 143 4,6 155 4.5
East Europe 402 2.9 64 0.9 112 3.6 226 6.5
Route of HIV acquisition MSM 6322 46.1 3377 47.3 1194 38.5 1751 50.7
IDU 1768 12.9 998 14.0 460 14.8 310 9.0
Heterosexual 4626 33.8 2213 31.0 1216 39.2 1197 34.7
Other/Unknown 987 7.2 559 7.8 232 7.5 196 5.7
Treatment experience/viral load (cp/
mL)
ART-naïve 4521 33.0 1914 26.8 1248 40.2 1359 39.3
ART-experienced, VL�200 cp/
mL
1213 8.9 538 7.5 500 16.1 175 5.1
ART-experienced, VL<200 cp/
mL
7969 58.2 4695 65.7 1354 43.6 1920 55.6
NRTI Backbone TDF/FTC 8158 59.5 3318 46.4 2139 69.0 2701 78.2
TAF/FTC 1116 8.1 727 10.2 33 1,1 356 10.3
ABC/3TC 3720 27,1 2692 37,7 722 23,3 306 8,9
Other 709 5.2 410 5.7 208 6,7 91 2.6
Prior AIDS Yes 2741 20.0 1606 22.5 640 20.6 495 14.3
Hepatitis B Positive 633 4.6 342 4.8 133 4.3 158 4.6
Hepatitis C Positive 2731 19.9 1598 22.4 628 20.2 505 14.6
BMI (kg/m2) �18 332 2.4 189 2.6 92 3.0 51 1.5
18–25 6143 44.8 3441 48.1 1282 41.3 1420 41.1
25–30 2716 19.8 1592 22.3 493 15.9 631 18.3
>30 877 6.4 499 7.0 170 5.5 208 6.0
Smoking Current 4241 30.9 2273 31.8 925 29.8 1043 30.2
Hypertension Yes 3402 24.8 2108 29.5 574 18.5 720 20.8
Diabetes Yes 731 5.3 482 6.7 109 3.5 140 4.1
Cardiovascular disease Yes 386 2.8 261 3.7 62 2.0 63 1.8
Chronic kidney disease Yes 400 2.9 295 4.1 66 2.1 39 1.1
Continuous variables Median (IQR) Median (IQR) Median (IQR) Median (IQR)
Age (years) 46 37–53 48 39–54 43 35–51 43 36–51
Baseline CD4 (cells/μL) 510 328–724 551 359–761 411 230–624 510 356–710
Nadir CD4 (cells/μL) 228 105–358 216 99–346 200 80–330 273 156–390
ARV drugs previous taken�(n) 6 3–8 6 4–9 5 3–8 5 3–7
Years since initiation of first ARV
(years)
11 6–17 13 7–18 10 5–16 8 4–14
(Continued)
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Table 1. (Continued)
All INSTI PI/b NNRTI
n % n % n % n %
13703 100.0 7147 52.2 3102 22.6 3454 25.2








All percentages are column percentages
The proportion of individuals with unknown/missing data were (%): Mode of transmission 6.8; ethnicity 11.8; hepatitis B 16.8; hepatitis C 13.8; BMI 29.5; smoking
status 39.0; hypertension 28.9; diabetes 8.5; cardiovascular disease 26.3; chronic kidney disease 19.2.
Regions: WestCentral Europe: Austria, Belgium, France, Germany, Luxembourg, Switzerland; South Europe and Argentina: Argentina, Greece, Israel, Italy, Portugal,
Spain; North Europe and Australia: Australia, Denmark, Norway, Sweden, Finland, Iceland, Ireland, Netherlands, United Kingdom; East Central Europe: Bosnia-
Herzegovina, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, Slovenia, Slovakia; Eastern Europe: Belarus, Estonia, Georgia, Latvia, Lithuania, Russia,
Ukraine.
Hypertension: Defined as use of antihypertensive drugs, systolic blood pressure>140 mmHg and/or diastolic blood pressure>90 mmHg.
Diabetes: A clinical diagnosis of diabetes, use of antidiabetic drugs and/or blood glucose measurement�11.1 mmol/l or HbA1C�48 mmol/mol.
HCV Positive: Positive if ever had a positive HCV antibody test, HCV RNA test, HCV genotype, or received HCV treatment prior to baseline. HBV positive: Hepatitis B
surface antigen positive
Chronic kidney disease: Defined as confirmed (>3 months apart) eGFR� 60 ml/min/1.73 m2, calculated by the CKD-EPI formula.
Cardiovascular disease includes prior myocardial infarction, stroke or invasive cardiovascular procedure.
�Among ART-experienced
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, anti-retroviral therapy; ARV, anti-retroviral drug; BMI, body-mass index; cp, copies of RNA; FTC, emtricitabine;
IDU, intravenous drug user; MSM, men who have sex with men; NRTI, nucleos(t)ide reverse transcriptase inhibitor; TDF: tenofovir disoproxil fumarate; TAF: tenofovir
alafenamide; VL, viral load.
All p-values for comparison of baseline characteristics between treatment groups were< 0,001.
https://doi.org/10.1371/journal.pone.0243625.t001
Fig 1. Proportions of individuals with composite treatment outcome (cTO) success, on-treatment success, or favorable immunologic response after 12±3
months. Error bars and numbers in the 3rd row in the table indicate 95% confidence intervals. � cTO failure was defined as�1 of VL�200 cp/mL, unknown VL, any
ART regimen change, AIDS events, or death. �� Individuals with known VL at 12±3 months without ART regimen change in the periods (N = INSTI 4513; PI/b 1721;
NNRTI 2263). ��� Persons with known CD4 counts at 12±3 months (N = INSTI 5823; PI/b 2550; NNRTI 2882). ����Persons with known CD4 counts at 12±3 months,
excluding those with�750 CD4 cells/μL at baseline (N = INSTI 4297; PI/b 2160; NNRTI 2253).
https://doi.org/10.1371/journal.pone.0243625.g001
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INSTIs (aOR 0.74 [CI 0.67–0.82], p<0.001; Fig 2A), while no significant difference was seen
when comparing NNRTIs and INSTIs (aOR 1.07 [0.97–1.17], p = 0.11).
The main reasons for cTO failure in all three treatment groups were regimen changes and
unknown VL within the time window (Fig 3). However, while proportions of individuals with
unknown VLs were similar between groups (16.1% [CI 15.3–17.0], 17.3% [16.0–18.6] and
17.0% [15.8–18.3], p = 0.26, for INSTIs, PI/b and NNRTIs respectively), regimen changes
occurred more often in the PI/b group, compared to the INSTI and NNRTI groups (31.6%
[30.0–33.3] vs. 24.4% [23.4–25.4] and 21.0% [19.7–22.4], p<0.001 respectively). In addition,
the number of individuals experiencing virologic failure in the PI/b group was higher in com-
parison with the INSTI and NNRTI group (5.4% [4.3–6.5] vs. 1.8% [1.4–2.2] and 2.2% [1.6–
2.8], p<0.001, respectively). Overall, the number of individuals developing AIDS (n = 201) or
who died during follow-up (n = 108) was low. However, there were some differences between
the groups. The proportion with AIDS was slightly higher in the PI/b group compared to the
INSTI and NNRTI group (2.5% [1.9–3.0] vs 1.3% [1.0–1.5] and 1.0% [0.7–1.3]; p<0.0001 for
comparison). The proportion of deaths was highest in the INSTI group and lowest in the
NNRTI group (1.0% [0.8–1.3], 0.8% [0.5–1.3] and 0.2% [0.1–0.4]; p< 0.0001).
Overall, 8,497/13,703 individuals (62.0%) were included in the on-treatment analyses
(53.1% on an INSTI, 20.3% on a PI/b and 26.6% on a NNRTI). The crude proportion of indi-
viduals achieving success was higher in the INSTI and NNRTI groups than in the PI/b group
(98.2% [CI 97.8–98.6] and 97.8% [97.2–98.4], respectively vs. 94.6% [93.5–95.7], p<0.001; Fig
1). Correspondingly, the aOR of on-treatment success was similar for the NNRTI group when
compared to the INSTI group (1.01 [0.67–1.52], p = 0.97), but significantly lower for the PI/b
group (0.60 [0.41–0.86], p = 0.01); Fig 2B).
Fig 2. Adjusted odds ratios (aOR) of composite treatment outcome (cTO) success and on-treatment success at 12±3 months. Forest plots showing the aOR of
cTO success (A) or on-treatment success (B). A controlled viral load was defined as<200 cp/mL. The multivariable models were adjusted for: Age (per ten years
older), ethnicity, mode of transmission, baseline date (per year later), baseline smoking status, hypertension, diabetes, HBV and HCV status, prior AIDS event,
cardiovascular disease, chronic kidney disease, end stage liver disease, non-AIDS-defining malignancies and prior fractures, viral load(<200 cp/mL,�200 cp/mL at
baseline) and treatment status, CD4 count (nadir and baseline; both per 100 cells higher), treatment regimen and number of drugs in regimen. � cTO failure was
defined as�1 of VL�200 cp/mL, unknown VL, any ART regimen change, AIDS events, or death. �� Individuals with known VL at 12±3 months without ART
regimen change in the period.
https://doi.org/10.1371/journal.pone.0243625.g002
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Immunologic outcomes
In total, 11,255/13,703 (82.1%) individuals had CD4 measurements available after 12±3
months (51.7% on an INSTI, 22.7%, on a PI/b and 25.6% on an NNRTI). The crude propor-
tion of individuals achieving a 25% increase in CD4 count from baseline was lowest for indi-
viduals on INSTIs compared to individuals on PI/b or NNRTIs (41.2% [CI 40.0–42.4] vs.
53.0% [51.4–55.3] or 44.6% [42.6–46.4]; p<0.001, respectively; Fig 1). However, after adjust-
ments, individuals on a PI/b or NNRTI had significantly lower odds of achieving a 25% CD4
cell increase, compared to those on an INSTI (0.87 [0.76–0.99], p = 0.04 and 0.80 [0.71–0.91],
p<0.001 respectively; Fig 4A).
Of participants with available CD4 counts 8,710 (77.4%) had a CD4 count<750 cells/μL at
baseline and could be assessed for achieving a CD4 count�750 cells/μL(49.3% on an INSTI,
24.8% on a PI/b and 25.9% on a NNRTI). The crude proportion reaching this level was higher
in the INSTI group than in both the PI/b and NNRTI groups (20.9% [19.9–21.9] vs 15.6%
[14.3–16.9] and 18.2% [16.9–19.5], p<0.001; Fig 1). After adjustment, compared to individu-
als on an INSTI, those on a PI/b or an NNRTI had lower odds of achieving a CD4 count�750
cells/μL (aOR 0.84 [0.70–1.01], p = 0.06 or 0.62 [0.52–0.72], P<0.001 respectively; Fig 4B),
although this did not reach statistical significance for the PI/b group.
Subgroup analyses
The proportions of individuals with cTO success, on-treatment success, a 25% increase in
CD4 cell numbers or reaching a CD4 count of�750 cells/μL, stratified into the three pre-spec-
ified sub-groups, followed the trends of the overall analyses (S2 Table). Similarly, reasons for
cTO failure by treatment status at baseline followed the trends of the overall analyses (see S3
Table and S1 Fig).
Fig 3. Reasons for cTO failure at 12±3 months. Error bars and 3rd row in the table indicate 95% confidence intervals. Total numbers with cTO failure: INSTI: 2749/
7147; PI/b: 1396/3102; NNRTI 1253/3454. �cTO failure:�1 of: VL�200 cp/mL, unknown VL, any antiretroviral treatment (ART)-regimen change, AIDS, or death
(note it was possible to fail more than one parameter).
https://doi.org/10.1371/journal.pone.0243625.g003
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In adjusted analyses, achieving cTO success, on-treatment success or a 25% increase in
CD4 count did not differ according to ART- and viremia-status at baseline (p>0.05 for all
interactions; Figs 2 and 4A), although there was some evidence suggesting that reaching a CD4
count of�750 cells/μL differed between strata (interaction p = 0.015; Fig 4B). Among ART-
experienced individuals with a baseline VL�200, those treated with an NNRTI were signifi-
cantly more likely to reach�750 cells/μL compared to those on INSTIs, in contrast to the
results in the overall analysis.
Sensitivity analyses
When a VL cut-off of<50 cp/mL was used to define cTO (Fig 5A) and on-treatment success
(Fig 5B), results were entirely consistent with the primary analysis. Likewise, cTO results were
similar when adjusting for cohort rather than comorbidities, or when individuals with
unknown VL at 12±3 months were excluded from the cTO definition (S2 Fig).
Excluding either any regimen changes from the cTO definition, or not defining NRTI-
backbone changes as regimen changes, both caused cTO success to become slightly less likely
for NNRTIs, whereas the relationship between INSTIs and PI/b did not change (see S2 Fig).
Analyses from ART-naïve individuals initiating treatment after January 2014, were similar
to the primary analyses (Fig 6).
Discussion
Here we present for the first time real-world data from a large, heterogeneous and geographi-
cally diverse multicenter cohort consortium, comparing virologic and immunologic outcomes
of treatment with INSTI-containing regimens to contemporary PI/b- and NNRTI-containing
regimens. Looking at outcomes after 12 months, using several different definitions for
Fig 4. Adjusted odds ratios (aOR) of a favorable immunologic response at 12±3 months. Immunologic response was defined as a 25% increase in CD4 cell counts
(A) or reaching a CD4 cell count�750 cells/μL (B). Models were adjusted for age (per ten years older), ethnicity, mode of transmission, baseline date (per year later),
baseline smoking status, hypertension, diabetes, HBV and HCV status, prior AIDS event, cardiovascular disease, chronic kidney disease, end stage liver disease, non-
AIDS-defining malignancies and prior fractures, viral load (<200 cp/mL,�200 cp/mL at baseline) and treatment status, CD4 count (nadir and baseline; both per 100
cells higher), treatment regimen and number of drugs in regimen. �Excluding individuals with a CD4 cell count�750 cells/μL at baseline.
https://doi.org/10.1371/journal.pone.0243625.g004
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virologic and immunologic outcome, INSTI- and NNRTI-based regimens were, indepen-
dently of previous treatment and ongoing viremia at treatment start or switch, consistently
associated with higher rates of treatment durability and virologic efficacy than PI/b-based regi-
mens. Further, favorable immunologic outcomes were more likely for individuals treated with
INSTIs than for individuals treated with NNRTIs and, to a lesser degree, with a PI/b. Here we
extend findings from previous RCTs and observational studies [1, 2, 4, 5, 7, 16–19], adding
novel evidence favoring INSTI treatment for the general population of PLWH seen in routine
clinical care.
Virologic outcomes
The higher likelihood of cTO success for individuals treated with INSTIs or NNRTIs, com-
pared to individuals treated with a PI/b, was partly due to more frequent regimen changes in
the latter group. Though lesser availability of PI/b-containing single-tablet regimes may have
contributed to some of these changes, PI/b are well known for having a higher potential for
drug-drug interactions and adverse effects, such as gastrointestinal symptoms, than INSTIs
and NNRTIs [9].
Previous findings within RESPOND [20] have confirmed that INSTI toxicity only accounts
for approximately 5% of the reasons for INSTI discontinuations, similar to findings from the
Swiss cohort study [21]. Likewise, a recent, large online-questionnaire examination from the
Brazilian Ministry of Health found that only 2.2% of participants experienced self-reported
dolutegravir toxicity.
Results from these prior reports, along with our results showing fewer regimen changes on
INSTIs, indicate that, although specific toxicities may be overrepresented in individuals treated
Fig 5. Sensitivity analysis: Adjusted odds ratios (aOR) of cTO and on-treatment analysis with VL cut-off<50 cp/mL at 12±3 months.Multivariable models were
adjusted for age (per ten years older), ethnicity, mode of transmission, baseline date (per year later), smoking status, hypertension, diabetes, prior AIDS event-
cardiovascular disease, chronic kidney disease, end stage liver disease, non-AIDS-defining malignancies and fractures, HBV and HCV status, viral load (<200 cp/mL,
�200 cp/mL at baseline), CD4 count (nadir and baseline; both per 100 cells higher), treatment regimen and number of drugs in regimen. � cTO failure was defined as
�1 of VL�50 cp/mL, unknown VL, any ART regimen change, AIDS events, or death. �� Individuals with known VL at 12±3 months without ART regimen change in
the period.
https://doi.org/10.1371/journal.pone.0243625.g005
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with specific INSTIs (e.g. neuropsychiatric adverse events with dolutegravir) [20–22], short
term INSTI toxicities still appear to be infrequent.
Both cTO and on-treatment analysis revealed a lower likelihood of virologic control for
individuals treated with a PI/b compared to an INSTI, as has previously been described [2, 6,
23, 24]. Although we found statistically significant differences in efficacy, all three drug classes
individually demonstrated high levels of viral suppression. Further, we found some differences
in the crude proportions of AIDS events and deaths between classes over 12 months follow-
up. In addition to the higher rates of virologic failure, a larger proportion of individuals in the
PI/b group experienced an AIDS defining event during the assessed period. Darunavir/b has a
high genetic barrier and was the most frequently prescribed PI/b in this analysis. We are there-
fore unable to fully exclude the possibility that some of this may be related to confounding by
indication. The larger proportion of deaths in the INSTI group could similarly be attributed to
confounding by indication, with those in the INSTI group generally being older, more treat-
ment-experienced, and having more comorbidities. Longer term follow-up in large cohort col-
laborations will be essential to determine whether the relatively modest differences observed
here can be explained by adjustment for potential confounding factors or if they will become
more pronounced over time.
Fig 6. Adjusted odds ratios of cTO success, on-treatment success and favorable immunologic outcomes at 12 ± 3
months for ART-naïve individuals initiating treatment after 16th January 2014. Forest plots showing the aOR of
cTO success, on-treatment success, and immunologic response as a 25% increase in CD4 cell counts or reaching a CD4
cell count�750 cells/μL. A controlled viral load was defined as<200 cp/mL. Multivariable models were adjusted for
age (per ten years older), ethnicity, mode of transmission, baseline date (per year later), baseline smoking status,
hypertension, diabetes, HBV and HCV status, prior AIDS event, cardiovascular disease, chronic kidney disease, end
stage liver disease, non-AIDS-defining malignancies and prior fractures, viral load (<200 cp/mL,�200 cp/mL at
baseline), CD4 count (nadir and baseline; both per 100 cells higher, treatment regimen and number of drugs in
regimen. �cTO failure was defined as�1 either of VL�200 cp/mL, unknown VL, ART regimen change, AIDS events,
or death. �� Individuals with known VL at 12±3 months without ART regimen change in the period. ���Excluding
individuals with�750 CD4 cells/μL at baseline.
https://doi.org/10.1371/journal.pone.0243625.g006
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The proportions of individuals with unknown VL within the 12±3 months time window
were relatively high for all three drug classes and without inter-class difference, as also reflected
by the consistent results when excluding unknown VL from the cTO. While current recom-
mendations suggest that VL should be measured at least every twelve months for individuals
on stable ART, and more frequently following regimen switches [8–11], it is not unreasonable
to assume that real-life practice differs on national levels, and more time can pass—in particu-
larly for treatment compliant individuals with suppressed viremia.
As this is an observational study, we cannot with certainty determine whether the lack of
VL measurements was a consequence of data not being reported to RESPOND, or of tests not
being performed locally within the time period. However, quality assessments are performed
as RESPOND data is electronically transferred from all participating sites [14, 25], and there-
fore it is unlikely that a significant amount of the unknown VLs are due to systematic underre-
porting to RESPOND.
Immunologic outcome
We saw only a very small difference in the likelihood of a 25% increase in CD4 count between
INSTIs and PI/b, and no difference in the likelihood of achieving�750 CD4 cells/μL between
the two ARV classes, consistent with prior reports [6, 7]. Similarly to previously findings from
large observational studies and RCTs comparing dolutegravir [5, 18] and elvitegravir [4] to efa-
virenz, we found that individuals treated with NNRTI-containing regimens were less likely to
achieve a favorable immunologic response compared to INSTIs, even with rilpivirine added to
the NNRTI group in our analysis.
Although the differences found between drug classes were minor, the potential effect on
ongoing inflammation and longer-term disease progression is to date not known. Therefore, it
will be imperative to observe if these differences will be associated with more frequent adverse
outcomes over longer periods of time.
Subgroup analyses
Although there was some evidence suggesting that reaching a CD4 count�750 cells/μL dif-
fered slightly according to ART status and level of viremia at baseline, we saw no evidence of a
subgroup effect on any of the other outcomes, and the results should be interpreted accord-
ingly with multiple testing in mind. Specifically, for the assessment of outcomes for ART-
experienced individuals with VL�200 cp/mL at baseline, it should be noted, that due to the
comparatively lower resistances barrier of NNRTIs, clinicians may be reluctant to prescribe
this drug class to ART-experienced individuals with ongoing viremia, likely reflected in the
low number of individuals on NNRTIs in this stratum.
Overall, these findings suggest that INSTIs can safely be used regardless of treatment status
and history at treatment initiation, though more studies with comprehensive data on resis-
tance testing is still needed.
Interactions between high VL, low CD4 counts and age with virologic and immunologic
outcomes have been investigated in another RESPOND analysis, where no differences were
seen between these individuals treated with INSTIs, PI/b and NNRTIs [26].
Limitations
There are some study limitations to acknowledge. Firstly, our study is observational in nature,
and although our analyses included adjustment for a wide range of potential confounders, and
several sensitivity and subgroup analyses were performed, residual confounding can never be
fully excluded, and our results should be interpreted accordingly. In particular, RESPOND
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does not systematically collect data on ARV-resistance nor HIV-subtypes, which can affect
treatment choice, especially in the strata of ART-experienced individuals with VL�200 cp/mL
at baseline.
Secondly, as we wanted to ensure adequate power to reliably analyse outcomes and perform
predefined subgroup analyses and test for potential interactions, we focused on class effects
rather than on individual ARVs. Therefore, it is possible that there may be some intra-class dif-
ferences not accounted for here. Finally, our analyses were restricted to a 12 months period,
and we therefore cannot make any statements on longer-term outcomes. Longer follow-up on
individual ARVs is required to allow for individual comparisons, as well as assessment of lon-
ger term clinical outcomes including serious non-AIDS clinical events.
Conclusion
In conclusion, this large, real-world based analysis of a heterogeneous population of PLWH
seen in routine clinical care, showed that treatment with INSTI and NNRTI-containing
regimes was preferable to PI/b with regard to virologic outcomes, although the potential for
residual confounding cannot be fully excluded. Favorable immunologic responses were more
likely with INSTI-containing regimens than with NNRTI-containing regimens, and to a lesser
degree with PI/b-containing regimens. Crude numbers did not reveal any major differences in
the occurrence of AIDS or death. These data supports the use of INSTI treatment and suggest
that 12 months efficacy and durability of INSTIs are independent of prior treatment status and
on-going viremia.
Supporting information
S1 Table. Baseline demographics and clinical characteristics of individuals stratified by
treatment status at baseline. All percentages are column percentages. The proportion of
individuals with unknown/missing data were (%): Mode of transmission 6.8; ethnicity 11.8;
hepatitis B 16.8; hepatitis C 13.8; BMI 29.5; smoking status 39.0; hypertension 28.9; diabetes
8.5; cardiovascular disease 26.3; chronic kidney disease 19.2. Regions: West Central Europe:
Austria, Belgium, France, Germany, Luxembourg, Switzerland; South Europe and Argen-
tina: Argentina, Greece, Israel, Italy, Portugal, Spain; North Europe and Australia: Australia,
Denmark, Norway, Sweden, Finland, Iceland, Ireland, Netherlands, United Kingdom; East
Central Europe: Bosnia-Herzegovina, Croatia, Czech Republic, Hungary, Poland, Romania,
Serbia, Slovenia, Slovakia; Eastern Europe: Belarus, Estonia, Georgia, Latvia, Lithuania, Rus-
sia, Ukraine. Hypertension: Defined as use of antihypertensive drugs, systolic blood pressure
>140 mmHg and/or diastolic blood pressure >90 mmHg. Diabetes: A clinical diagnosis of
diabetes, use of antidiabetic drugs and/or blood glucose measurement �11.1 mmol/l or
HbA1C �48 mmol/mol. HCV Positive: Positive if ever had a positive HCV antibody test,
HCV RNA test, HCV genotype, or received HCV treatment prior to baseline. HBV positive:
Hepatitis B surface antigen positive. Chronic kidney disease: Defined as confirmed (>3
months apart) eGFR� 60 ml/min/1.73 m2, calculated by the CKD-EPI formula. Cardiovas-
cular disease includes prior myocardial infarction, stroke or invasive cardiovascular proce-
dure. �Among ART-experienced. Abbreviations: 3TC, lamivudine; ABC, abacavir; ART,
anti-retroviral therapy; ARV, anti-retroviral drug; BMI, body-mass index; cp, copies of
RNA; FTC, emtricitabine; IDU, intravenous drug user; MSM, men who have sex with men;
NRTI, nucleos(t)ide reverse transcriptase inhibitor; TDF: tenofovir disoproxil fumarate;
TAF: tenofovir alafenamide; VL, viral load. All p-values for comparisons were< 0.001.
(PDF)
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S2 Table. Numbers and proportions of individuals with cTO success, on-treatment success
and immunologic responses at 12 ± 3 months, stratified by treatment status at baseline.
�cTO success defined as a VL<200 cp/mL. in individuals without failure (at least one of: VL
�200 cp/mL, unknown VL, ART regimen change, AIDS events or death). ��persons with
known VL at 12±3 months without regimen changes (N = INSTI 4513; PI/b 1721; NNRTI
2263). ���persons with known CD4 counts at 12±3 months (N = INSTI 5823; PI/b 2550;
NNRTI 2882). ����persons with known CD4 counts at 12±3 months excluding persons with
�750 CD4 cells/μL at baseline (N = INSTI 4297; PI/b 2160; NNRTI 2253).
(PDF)
S3 Table. Reasons for cTO failure� according to treatment status at baseline. �cTO failure
was defined as at least one of: VL�200 cp/mL, unknown VL, any antiretroviral treatment
(ART)-regimen change, AIDS, or death (note that it is possible to fail more than one parame-
ter). �� number of specific reasons for cTO failure. ���persons with known VL at 12±3 months
without regimen changes.
(PDF)
S1 Fig. Reasons for cTO failure according to treatment status at baseline. �persons with
known VL at 12±3 months, without regimen changes. Numbers above each column indicate
the total number of the specific reasons for cTO failure overall, and for each of the treatment
groups (INSTI, bPI or NNRTI). Numbers in the bars indicate percent of total. The table below
the bars shows the numbers individuals with each specific reason for cTO failure by treatment
group, stratified by treatment status at baseline. Note that individuals could fail the cTO out-
come for more than one reasons.
(TIF)
S2 Fig. Forest plots of sensitivity analyses investigating cTO under different conditions.Mul-
tivariable models were adjusted for age (per ten years older), ethnicity, mode of transmission,
baseline date (per year later), smoking status, hypertension, diabetes, prior AIDS event- cardio-
vascular disease, chronic kidney disease, end stage liver disease, non-AIDS-defining malignan-
cies and fractures, HBV and HCV status, viral load (<200 cp/mL,�200 cp/mL at baseline), CD4
count (nadir and baseline; both per 100 cells higher), treatment regimen and number of drugs in
regimen. 1: aOR of cTO success defined as a VL<200 cp/mL. in individuals without failure (at
least one of: VL�200 cp/mL, unknown VL, cART regimen change, AIDS events or death). 2:
aOR of cTO success defined as in 1, at 6±3 months after baseline. 3 aOR of cTO success defined
as in 1, restricted to individuals initiating or shifting to one of the study regimens after 16th Janu-
ary 2014. 4 aOR of cTO success defined as in 1, restricted to ART-naïve individuals initiating
one of the study regimens after 16th January 2014. 5: aOR of cTO success defined as in 1, model
adjusted for cohort instead of comorbidities. 6: aOR of cTO success defined as a VL<200 cp/mL
in individuals without failure (at least one of: VL�200 cp/mL, unknown VL, AIDS events or
death; excluding ART regime changes from the main cTO outcome). 7: aOR of cTO success
defined as a VL<200 cp/mL in individuals without failure (at least one of: VL�200 cp/mL,
unknown VL, AIDS events, death or change of 3rd ARV (INSTI, PI/b or NNRTI); not defining
changes in NRTI backbone as an ART regimen change. 8: aOR of cTO defined as a VL<200 cp/
mL in individuals without failure (at least one of: VL�200 cp/mL, cART regimen change, AIDS
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